A new cardiovascular trial found tirzepatide cut major heart events by nearly 20% more than semaglutide, yet the older drug still leads in weight loss. Discover how these differences could shape obesity care.
For further actions, you may consider blocking this person and/or reporting abuse
Top comments (0)